MPD: Phenotype measures mapped to VT:0001392, locomotor behavior trait

Sort/ Pick	Data set	Procedure / Protocol	Treatment	Phenotype Measure / Variable (click to view)	Panel	No. of Strains	Sex	Age	Sample Size (Avg)	Year
Xenakis1:11	Xenakis1	inclined screen test	(none)	latency to move all four paws (extrapyramidal symptoms), placebo group [s] latency_cont 111154 pre-treatment post-treatment	CC RIX	73	both	7-9wks	N=3	2020

Xenakis1:13	Xenakis1	inclined screen test	haloperidol	latency to move all four paws (extrapyramidal symptoms), treatment group [s] latency_Rx 111156 pre-treatment post-treatment	CC RIX	73	both	7-9wks	N=3	2020

Xenakis1:15	Xenakis1	open field test	(none)	distance traveled, 30 min test, placebo group [cm] distance_cont 111158 pre-treatment post-treatment	CC RIX	73	both	7-13wks	N=3	2020

Xenakis1:17	Xenakis1	open field test	haloperidol	distance traveled, 30 min test, treatment group [cm] distance_Rx 111160 pre-treatment post-treatment	CC RIX	73	both	7-13wks	N=3	2020

Xenakis1:19	Xenakis1	open field test	(none)	vertical activity (beam breaks), 30 min test, placebo group [n] vertical_cont 111162 pre-treatment post-treatment	CC RIX	73	both	7-13wks	N=3	2020

Xenakis1:21	Xenakis1	open field test	haloperidol	vertical activity (beam breaks), 30 min test, treatment group [n] vertical_Rx 111164 pre-treatment post-treatment	CC RIX	73	both	7-13wks	N=3	2020

Xenakis1:23	Xenakis1	open field test	(none)	time spent in center of arena, 30 min test, placebo group [s] center_cont 111166 pre-treatment post-treatment	CC RIX	73	both	7-13wks	N=3	2020

Xenakis1:25	Xenakis1	open field test	haloperidol	time spent in center of arena, 30 min test, treatment group [s] center_Rx 111168 pre-treatment post-treatment	CC RIX	73	both	7-13wks	N=3	2020

Xenakis1:27	Xenakis1	open field test	(none)	stereotypy activity (beam breaks), 30 min test, placebo group [n] stereotypy_cont 111170 pre-treatment post-treatment	CC RIX	73	both	7-13wks	N=3	2020

Xenakis1:29	Xenakis1	open field test	haloperidol	stereotypy activity (beam breaks), 30 min test, treatment group [n] stereotypy_Rx 111172 pre-treatment post-treatment	CC RIX	73	both	7-13wks	N=3	2020

Xenakis1

inclined screen test

(none)

latency to move all four paws (extrapyramidal symptoms), placebo group [s] latency_cont 111154 pre-treatment post-treatment

CC RIX

73

both

7-9wks

N=3

2020

Xenakis1

inclined screen test

haloperidol

latency to move all four paws (extrapyramidal symptoms), treatment group [s] latency_Rx 111156 pre-treatment post-treatment

CC RIX

73

both

7-9wks

N=3

2020

Xenakis1

open field test

(none)

distance traveled, 30 min test, placebo group [cm] distance_cont 111158 pre-treatment post-treatment

CC RIX

73

both

7-13wks

N=3

2020

Xenakis1

open field test

haloperidol

distance traveled, 30 min test, treatment group [cm] distance_Rx 111160 pre-treatment post-treatment

CC RIX

73

both

7-13wks

N=3

2020

Xenakis1

open field test

(none)

vertical activity (beam breaks), 30 min test, placebo group [n] vertical_cont 111162 pre-treatment post-treatment

CC RIX

73

both

7-13wks

N=3

2020

Xenakis1

open field test

haloperidol

vertical activity (beam breaks), 30 min test, treatment group [n] vertical_Rx 111164 pre-treatment post-treatment

CC RIX

73

both

7-13wks

N=3

2020

Xenakis1

open field test

(none)

time spent in center of arena, 30 min test, placebo group [s] center_cont 111166 pre-treatment post-treatment

CC RIX

73

both

7-13wks

N=3

2020

Xenakis1

open field test

haloperidol

time spent in center of arena, 30 min test, treatment group [s] center_Rx 111168 pre-treatment post-treatment

CC RIX

73

both

7-13wks

N=3

2020

Xenakis1

open field test

(none)

stereotypy activity (beam breaks), 30 min test, placebo group [n] stereotypy_cont 111170 pre-treatment post-treatment

CC RIX

73

both

7-13wks

N=3

2020

Xenakis1

open field test

haloperidol

stereotypy activity (beam breaks), 30 min test, treatment group [n] stereotypy_Rx 111172 pre-treatment post-treatment

CC RIX

73

both

7-13wks

N=3

2020

Filter Table Results